A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Trial Profile

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METEOR
  • Sponsors Exelixis
  • Most Recent Events

    • 26 Mar 2018 Results assessing overall survival and updated safety after follow-up published in the British Journal of Cancer.
    • 15 Feb 2018 This trial has been completed in Germany according to European Clinical Trials Database
    • 10 Feb 2018 Results (n=282) of analysis assessing the effect of Carbozantinib on progression free survival and safety at different apparent clearance values presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top